FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial

June 24, 2019 – The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors t(11;14), according to AbbVie, the company that co-develops the BCL-2 inhibitor with Roche. The lift on the partial hold is based on an agreement on revisions to the CANOVA study protocol, which … (leggi tutto)